 |
 close |
||||||||
|
|
May 15th, 2003 Octapharma Sales grow by 36% Following the July 2002 acquisition of Biovitrum’s plasma division, Octapharma´s sales in 2002 grew by a staggering 36% (20% by organic growth and 16% through the acquisition). The merger of the two companies, who between them have over 70 years of experience of excellence in plasma fractionation, has decisively positioned Octapharma as a leading player in the global plasma derivatives market. Details of the acquisition and the resulting changes within the Octapharma group were announced this week through the publication of the company 2002 Annual Report. Octapharma was founded in 1983 and has seen year-on-year sales growth throughout its 20 years of operations. Headquartered in Switzerland, with fully integrated manufacturing facilities in Austria, France, Sweden and Mexico, Octapharma has subsidiaries and representative offices in 17 countries as well as a global distributor network. In 2002 Octapharma achieved gross sales of more than 306 million Euros. More than 65 million Euros were invested in research and development, fractionation capacity expansion, technical upgrading and the acquisition. The impressive sales growth and substantial investment programme combine to give Octapharma a solid foundation for even greater success in the future. If you would like to receive a copy of the 2002 Annual Report please click here. The Report is available in English, French and German so be sure to state your preference when ordering. Alternatively you may download the entire report or key sections of it below.
© Octapharma AG, 2003 |
